Kano Therapeutics

Executive Summary

Kano Therapeutics is a San Diego-based biotechnology company pioneering a novel DNA payload platform for cell and gene therapy. Its core technology, circular single-stranded DNA (cssDNA), offers a safer, more efficient, and scalable alternative to traditional viral vectors or double-stranded DNA templates. cssDNA enables both permanent genomic insertion and re-dosable genetic functions, addressing key limitations in current gene therapy approaches such as immunogenicity, limited cargo capacity, and production challenges. By leveraging its proprietary platform, Kano aims to expand the therapeutic potential of genetic medicines across a range of modalities, including ex vivo cell therapy and in vivo gene editing. The company is currently in the preclinical stage, with no disclosed funding or valuation, but its technology has generated interest due to its potential to overcome critical bottlenecks in the field. Kano's platform could enable safer, more durable, and repeatable treatments for genetic disorders, cancer, and other diseases. While still early-stage, the company's innovative approach positions it well for future growth. Upcoming milestones include preclinical data readouts, financing rounds, and IND-enabling studies, which will be key to validating its platform and advancing toward clinical development.

Upcoming Catalysts (preview)

• Q4 2026In vivo efficacy data readout for lead cssDNA candidate75% success
• Q2 2027Series A financing round close60% success
• Q3 2027IND filing for first therapeutic program50% success